Cadmium alters the biotransformation of carcinogenic aromatic amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: Molecular, cellular, and in vivo studies

Environmental Health Perspectives

Volumn 118, Issue 12, 2010, Pages 1685-1691

  Ragunathan, Nilusha ^a   Dairou, Julien ^a   Sanfns, Elodie ^a   Busi, Florent ^a   Noll, Christophe ^a   Janel, Nathalie ^a   Dupret, Jean Marie ^a   Rodrigues Lima, Fernando ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aromatic amine carcinogens; Arylamine N acetyltransferases; Cadmium; Irreversible inhibition; Xenobiotic metabolism

Indexed keywords

2 FLUORENYLAMINE; ACETYL COENZYME A; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CADMIUM; RECOMBINANT ENZYME;

ACETYLATION; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME PURIFICATION; FEMALE; IC 50; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICOKINETICS;

AMINES; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CADMIUM; CARCINOGENS; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; ISOENZYMES; MICE; MICE, INBRED C57BL; POLYCYCLIC HYDROCARBONS, AROMATIC; RESPIRATORY MUCOSA;

MUS;

EID: 78650299527     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1002334     Document Type: Article

References (49)

1. Agency for Toxic Substance and Disease Registry. 1997. Toxicological Profle for Cadmium. Atlanta, GA:Agency for Toxic Substance and Disease Registry.
2. Alary J, Carrera G, Lamboeuf Y, Escrieut C. 1989. Cadmium-induced alterations of chlorpropham metabolism in isolated rat hepatocytes. Toxicology 59:211-223.
3. Apostolova MD, Christova T, Templeton DM. 2006. Involvement of gelsolin in cadmium-induced disruption of the mesangial cell cytoskeleton. Toxicol Sci 89:465-474.
4. Badawi AF, Hirvonen A, Bell DA, Lang N P, Kadlubar FF. 1995. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55:5230-5237.
5. Bravard A, Vacher M, Gouget B, Coutant A, de Boisferon FH, Marsin S, et al. 2006. Redox regulation of human OGG1 activity in response to cellular oxidative stress. Mol Cell Biol 26:7430-7436.
6. Cornish-Bowden A. 2001. Fundamentals of Enzyme Kinetics. London:Portland Press.
7. Dairou J, Atmane N, Dupret JM, Rodrigues-Lima F. 2003. Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. Biochem Biophys Res Commun 307:1059-1065.
8. Dairou J, Petit E, Ragunathan N, Baeza-Squiban A, Marano F, Dupret JM, et al. 2009. Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicol Appl Pharmacol 236:366-371.
9. Dupret JM, Rodrigues-Lima F. 2005. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr Med Chem 12:311-318.
10. Elbekai RH, El-Kadi AO. 2007. Transcriptional activation and post transcriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. Toxicol Lett 172:106-119.
11. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. 2007. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 28:1287-1293.
12. Godschalk R, Hogervorst J, Albering H, Mercelina-Roumans P, van Schooten FJ, de Haan J, et al. 2005. Interaction between cadmium and aromatic DNA adducts in hprt mutagenesis during foetal development. Mutagenesis 20:181-185.
13. Grant DM, Blum M, Beer M, Meyer UA. 1991. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
14. Hein D, McQueen C, Grant D, Goodfellow G, Kadlubar F, Weber W. 2000. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425-1432.
15. Hein DW. 1988. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948:37-66.
16. Huff J, Lunn RM, Waalkes MP, Tomatis L, Infante PF. 2007. Cadmium-induced cancers in animals and in humans. Int J Occup Environ Health 13:202-212.
17. IARC (International Agency for Research on Cancer). 1993. Cadmium and cadmium compounds. IARC Monogr Eval Carcinog Risk Hum 58:119-237.
18. Jin YH, Clark AB, Slebos RJ, Al-Refai H, Taylor JA, Kunkel TA, et al. 2003. Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat Genet 34:326-329.
19. Joseph P. 2009. Mechanisms of cadmium carcinogenesis. Toxicol Appl Pharmacol 238:272-279.
20. Kawamura A, Westwood I, Wakefield L, Long H, Zhang N, Walters K, et al. 2008. Mouse N-acetyl transferase type 2, the homologue of human N-acetyltransferase type 1. Biochem Pharmacol 75:1550-1560.
21. Kil IS, Shin SW, Yeo HS, Lee YS, Park JW. 2006. Mitochondrial NADP+-dependent isocitrate dehydrogenase protects cadmium-induced apoptosis. Mol Pharmacol 70:1053-1061.
22. Kim D, Guengerich F P. 2005. Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27-49.
23. Liu L, Wagner CR, Hanna PE. 2008. Human arylamine N-acetyltransferase 1: in vitro and intracellular inactiva-tion by nitrosoarene metabolites of toxic and carcinogenic arylamines. Chem Res Toxicol 21:2005-2016.
24. Liu L, Wagner CR, Hanna PE. 2009. Isoform-selective inactiva-tion of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chem Res Toxicol 22:1962-1974.
25. Magdaleno SM, Wang G, Jackson KJ, Ray MK, Welty S, Costa RH, et al. 1997. Interferon-gamma regulation of Clara cell gene expression: in vivo and in vitro. Am J Physiol 272:L1142-L1151.
26. Maier A, Dalton T P, Puga A. 2000. Disruption of dioxin-inducible phase I and phase II gene expression patterns by cadmium, chromium, and arsenic. Mol Carcinog 28:225-235.
27. Martelli A, Rousselet E, Dycke C, Bouron A, Moulis JM. 2006. Cadmium toxicity in animal cells by interference with essential metals. Biochimie 88:1807-1814.
28. Martin LJ, Chen H, Liao X, Allayee H, Shih DM, Lee GS, et al. 2007. FK506, a calcineurin inhibitor, prevents cadmium-induced testicular toxicity in mice. Toxicol Sci 100:474-485.
29. McNeill DR, Narayana A, Wong HK, Wilson DM III. 2004. Inhibition of Ape1 nuclease activity by lead, iron, and cadmium. Environ Health Perspect 112:799-804.
30. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. 2007. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 39:1999-2005.
31. Minchin RF, Kadlubar FF, Ilett KF. 1993. Role of acetylation in colorectal cancer. Mutat Res 290:35-42.
32. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
33. Mushtaq A, Payton M, Sim E. 2002. The C-terminus of aryl mine N-acetyl transferase from Salmonella typhimurium controls enzymic activity. J Biol Chem 17:12175-12181.
34. National Toxicology Program. 2005. 11th Report on Carcinogens. Research Triangle Park, NC:National Toxicology Program.
35. Oreffo VI, Morgan A, Richards RJ. 1990. Isolation of Clara cells from the mouse lung. Environ Health Perspect 85:51-64.
36. Palmiotto G, Pieraccini G, Moneti G, Dolara P. 2001. Determination of the levels of aromatic amines in indoor and outdoor air in Italy. Chemosphere 43:355-361.
37. Potts RJ, Bespalov IA, Wallace SS, Melamede RJ, Hart BA. 2001. Inhibition of oxidative DNA repair in cadmium-adapted alveolar epithelial cells and the potential involvement of metallothionein. Toxicology 161:25-38.
38. Prakash AS, Tran HP, Peng C, Koyalamudi SR, Dameron CT. 2000. Kinetics of DNA alkylation, depurination and hydrolysis of anti diol epoxide of benzo(a)pyrene and the effect of cadmium on DNA alkylation. Chem Biol Interact 125:133-150.
39. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, et al. 2008. Identification of the xenobiotic-me-tabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) as a new target of cisplatin in breast cancer cells. Mol Pharmacol 73:1761-1768.
40. Rivedal E, Sanner T. 1981. Metal salts as promoters of in vitro morphological transformation of hamster embryo cells initiated by benzo(a)pyrene. Cancer Res 41:2950-2953.
41. Smelt VA, Upton A, Adjaye J, Payton MA, Boukouvala S, Johnson N, et al. 2000. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet 9:1101-1107.
42. Stavrides JC. 2006. Lung carcinogenesis: pivotal role of metals in tobacco smoke. Free Radic Biol Med 41:1017-1030.
43. Vakharia DD, Liu N, Pause R, Fasco M, Bessette E, Zhang QY, et al. 2001. Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepa-tocyte cultures. Toxicol Appl Pharmacol 170:93-103.
44. Waalkes M P. 2003. Cadmium carcinogenesis. Mutat Res 533:107-120.
45. Whiteside JR, Box CL, McMillan TJ, Allinson SL. 2010. Cadmium and copper inhibit both DNA repair activities of poly nucleo-tide kinase. DNA Repair (Amst) 9:83-89.
46. 3H]benzo[a] pyrene. Environ Res 34:212-226.
47. Wu HC, Lu HF, Hung CF, Chung JG. 2000. Inhibition by vitamin C of DNA adduct formation and arylamine N-acetyltransferase activity in human bladder tumor cells. Urol Res 28:235-240.
48. Yuan C, Kadiiska M, Achanzar WE, Mason R P, Waalkes M P. 2000. Possible role of caspase-3 inhibition in cadmium-induced blockage of apoptosis. Toxicol Appl Pharmacol 164:321-329.
49. Zharkov DO, Rosenquist TA. 2002. Inactivation of mammalian 8-oxoguanine-DNA glycosylase by cadmium(II): implications for cadmium genotoxicity. DNA Repair (Amst) 1:661-670.